Gilead Sciences, Inc. (GILD): Business Model Canvas [June-2026 Updated]

This ready-made Business Model Canvas of Gilead Sciences, Inc. gives you a research-based view of a global biopharma business built on HIV leadership, long-acting prevention, oncology, inflammation, and global access through 120+ country HIV licensees. You'll see how the company creates value through Phase 3 development, AI-enabled drug discovery, global manufacturing, and FDA trial collaboration, then captures it through HIV, oncology, COVID-19, inflammation, and international licensing revenue, while serving HIV treatment and prevention patients, oncology patients and oncologists, liver disease patients, and global access markets through hospitals, specialist prescribers, specialty pharmacies, and direct commercial teams, with major resources including 17,000+ employees, $10.0B in cash and securities, and cost drivers such as R&D, manufacturing, $32.0B in capital investments, licensing payments, and litigation.

Gilead Sciences, Inc. - Canvas Business Model: Key Partnerships

Genesis Therapeutics: $35 million upfront; up to $1.5 billion in potential milestone payments.

Janssen: $1.1 billion royalty buyout.

HIV licensees: 120+ countries.

FDA and trial collaborators: 1 FDA approval in 2022; 2 Phase 3 studies; 5,338 participants in PURPOSE 1.

• Genesis Therapeutics: $35 million
• Genesis Therapeutics: up to $1.5 billion
• Janssen: $1.1 billion
• HIV licensees: 120+ countries
• FDA and trials: 1 approval; 2022; 2 Phase 3 studies; 5,338 participants

Gilead Sciences, Inc. - Canvas Business Model: Key Activities

3 late-2025 activity clusters define Gilead Sciences, Inc.: HIV R&D, oncology R&D, and inflammation R&D. The commercial engine is built around 1-tablet daily oral therapy, 2-injection-per-year prevention, and 1-infusion cell therapy.

HIV, oncology, inflammation R&D: Gilead Sciences, Inc. runs 3 therapeutic-area workstreams. In HIV, the commercial model centers on 1-tablet daily treatment and 2-dose-per-year prevention. In oncology, the model splits between 2 approved CAR-T therapies and 1 antibody-drug conjugate, which means both individualized cell manufacturing and scalable biologics development matter. In inflammation, the $4.3 billion CymaBay Therapeutics acquisition added seladelpar to the portfolio and expanded the company's non-HIV growth base.

Phase 3 clinical development: the late-stage pipeline depends on 3 PURPOSE studies for lenacapavir prevention: PURPOSE 1, PURPOSE 2, and PURPOSE 3. That matters because phase 3 is the last large test before approval, so it is where efficacy, safety, and dosing convenience are converted into label claims and pricing power.

• 3 PURPOSE studies for lenacapavir prevention
• 2 injections per year for the commercial prevention regimen
• 1 regulatory package moving from phase 3 data to FDA review

AI-enabled drug discovery: in 2024, Gilead Sciences, Inc. added 1 AI collaboration with Genesis Therapeutics. The strategic value is in faster target selection, faster hit finding, and fewer failed compounds before phase 1, which lowers the cost of each approved molecule if the platform keeps producing viable candidates.

Global manufacturing scale-up: Gilead Sciences, Inc. operates across 3 manufacturing archetypes: oral small molecules, antibody-drug conjugates, and autologous cell therapy. Cell therapy is the most complex because it requires 1 patient-specific lot per infusion, while oral HIV products require wide global supply for 1-tablet daily use and long-acting prevention products require synchronized release planning for 2 injections per year.

Commercial launch execution: June 18, 2025 is the key launch date for Yeztugo. That launch turns a 2-injection-per-year prevention regimen into a marketable product, so execution depends on physician education, access, reimbursement, and supply availability from day 1.

Oncology execution: Gilead Sciences, Inc. manages 2 CAR-T launches and 1 ADC launch at the same time, which makes manufacturing slots, site onboarding, and channel inventory more important than in a standard oral-drug launch. The commercial task is not just selling therapy; it is also keeping 1 personalized infusion chain and 1 global oncology supply chain moving without delays.

Gilead Sciences, Inc. - Canvas Business Model: Key Resources

5 branded assets, 17,000+ global employees, and $10.0B in cash and securities are the main late-2025 resources behind Gilead Sciences, Inc.

Biktarvy and Yeztugo give Gilead Sciences, Inc. a mix of 1-pill daily treatment and 2-dose yearly prevention. That combination is unusual in HIV because it links an established treatment brand with a long-acting prevention brand.

Trodelvy, Veklury, and Livdelzi add 3 more named assets across oncology, virology, and liver disease. The set of 5 brands reduces reliance on a single product line, even though Biktarvy alone delivered $13.4B in 2024 sales.

• 17,000+ global employees
• $10.0B cash and securities
• 333 Lakeside Drive, Foster City, CA 94404
• 1 Foster City headquarters and research site
• 2 Yeztugo doses per year
• 3-day Veklury outpatient regimen

Gilead Sciences, Inc. - Canvas Business Model: Value Propositions

Leading HIV treatment portfolio

7 marketed HIV medicines: Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, Truvada, and Sunlenca.

• 1-tablet regimens: Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, Truvada
• 3-drug regimens: Biktarvy, Odefsey
• 4-drug regimens: Genvoya, Symtuza
• 2-drug regimens: Descovy, Truvada
• 1-drug long-acting regimen: Sunlenca

Long-acting HIV prevention

PURPOSE 1: 2,134 participants, 0 HIV infections in the lenacapavir arm, 99.9% reported incidence reduction.

PURPOSE 2: 2,180 participants, 2 HIV infections in the lenacapavir arm, 96% reported incidence reduction.

• 6-month prevention interval
• 2 phase 3 prevention trials
• 0 infections in the PURPOSE 1 lenacapavir arm
• 2 infections in the PURPOSE 2 lenacapavir arm

Oncology options for solid tumors

Trodelvy: 2 U.S. solid-tumor indications.

• 2 approved metastatic breast cancer settings
• 2 pivotal datasets for the solid-tumor platform
• 12.1 months and 14.4 months median overall survival in key trials

New inflammation therapy entry

CymaBay Therapeutics acquisition value: $4.3 billion.

Added assets: 1 late-stage inflammation/liver program.

• $4.3 billion transaction value
• 1 acquired lead asset
• 1 new therapeutic area added through acquisition

Global access through licensing

Voluntary licensing footprint: 127 countries.

• 127 countries in the access territory
• 1 licensing-based access model

Gilead Sciences, Inc. - Canvas Business Model: Customer Relationships

Gilead Sciences, Inc. builds customer relationships around long-duration treatment, specialist prescribers, and access support. The model depends on chronic use, with 3 core therapeutic areas and 2 approved CAR-T therapies that need close follow-up, referral networks, and safety monitoring.

Chronic care and adherence support

Gilead Sciences, Inc. relies on relationships that last for years, not weeks. That is especially true in HIV and hepatitis B, where treatment is often long term and adherence matters every day. Support usually centers on refill continuity, insurance navigation, copay help, and patient education. In this model, a missed dose can weaken outcomes, so relationship quality affects both health results and revenue durability. The company's chronic-care base is also reinforced by treatment switching, where physicians move patients to newer regimens with simpler dosing, fewer interactions, or better tolerability. That keeps the customer relationship active even after the first prescription.

• Long-duration therapy increases the value of retention over single-sale transactions.
• Adherence support matters because chronic viral disease management depends on consistent dosing.
• Insurance and access help can reduce treatment interruptions.
• Switching to newer regimens keeps the prescriber relationship with Gilead Sciences, Inc. in place.

Specialist physician engagement

Gilead Sciences, Inc. does not depend on broad consumer marketing. It depends on specialist doctors who diagnose, start, and monitor complex therapies. In HIV, that means infectious disease specialists and primary care doctors with HIV experience. In liver disease, it means hepatologists and gastroenterologists. In oncology and cell therapy, it means cancer specialists and centers that can handle infusion, monitoring, and toxicity management. The relationship is technical because the therapies are technical. For CAR-T, the physician relationship extends beyond prescribing to referral, preparation, infusion, and follow-up. That makes the doctor, not the patient alone, a core part of the customer relationship.

• Specialists drive initiation, switching, and long-term continuation.
• Cell therapy depends on trained centers rather than mass retail distribution.
• Post-treatment monitoring keeps the relationship active after the infusion date.
• Clinical education has direct business value because it shapes adoption in high-complexity care.

Long-term patient treatment access

Long-term access is central to Gilead Sciences, Inc. because many of its therapies are used continuously or preventively. The company has 2 U.S.-approved HIV PrEP medicines, which makes access, affordability, and adherence support part of the product relationship itself. Patients often need help with insurance approval, pharmacy access, and out-of-pocket cost pressure. For chronic therapy, a good customer relationship is not just a sale; it is the ability to keep the patient on therapy without interruption. That is why reimbursement support, specialty pharmacy coordination, and patient assistance are commercially important. If access breaks down, the patient can stop therapy, and the relationship weakens immediately.

• 2 U.S.-approved HIV PrEP medicines support a prevention-based access model.
• Affordability help protects persistence in chronic treatment.
• Specialty pharmacy coordination reduces friction at the point of fill.
• Access continuity matters because long-term treatment is more valuable than a one-time prescription.

Voluntary licensing partnerships

Gilead Sciences, Inc. uses voluntary licensing as a relationship tool in lower-income markets. The model is nonexclusive, which means it can work through multiple generic manufacturers rather than a single commercial channel. That matters in HIV and other antiviral access because broad supply can lower barriers to treatment in countries where branded pricing would limit uptake. These partnerships also reduce tension with public health systems by making access part of the business model instead of an afterthought. In practice, the relationship is not with one end customer alone; it is with governments, procurement systems, generic producers, and global health buyers. That makes the company's access strategy a network relationship, not a direct retail one.

• Nonexclusive licensing broadens supply capacity.
• Generic partners improve reach in lower-income markets.
• Public health buyers become part of the customer network.
• Access terms can support both treatment scale and reputational trust.

Regulatory and safety oversight

Gilead Sciences, Inc. operates under heavy regulatory and safety oversight because its therapies can be long term, high risk, or highly specialized. Safety management includes label updates, adverse-event reporting, post-marketing studies, and restricted-use controls where needed. CAR-T therapies are a clear example of this relationship type because they depend on trained treatment centers and formal monitoring rules. The company's relationship with regulators is also part of the customer model because compliance affects whether a product can stay on the market and how easily physicians can use it. In this setting, trust is built through safety data, not marketing language.

• REMS-linked products require stricter use and monitoring rules.
• Adverse-event reporting keeps regulators and physicians connected to the product lifecycle.
• Post-marketing safety work supports ongoing market access.
• Safety controls matter more for advanced therapies than for simple retail medicines.

Gilead Sciences, Inc. - Canvas Business Model: Channels

Hospital and specialist prescribers are the main channel for Gilead Sciences, Inc.'s infused oncology, cell therapy, and IV antiviral products. Yescarta and Tecartus are delivered as 1-time CAR-T infusions after cell collection and manufacturing, so the real gatekeepers are authorized treatment centers, not retail pharmacies. Trodelvy is given on days 1 and 8 of each 21-day cycle, which keeps oncologists and infusion suites at the center of access, scheduling, and monitoring. Veklury uses a 5-day inpatient course or a 3-day outpatient course, so hospital formulary placement and infusion capacity directly affect use.

Hospital and specialist prescribers matter because they control the most complex products in the portfolio. CAR-T treatment requires a specialized site, a treatment pathway, and coordination across collection, shipping, and infusion. That makes the channel expensive to enter but hard for competitors to copy. It also means one approved therapy can still have uneven uptake if enough sites are not trained or accredited. For academic writing, this channel shows how a biopharma company can sell a product only after it builds a clinical service network around it.

• Yescarta and Tecartus use a 1-infusion administration model after manufacturing.
• Trodelvy uses dosing on days 1 and 8 in a 21-day cycle.
• Veklury uses a 5-day or 3-day IV regimen depending on setting.
• These products depend on hospital inventory, specialist training, and treatment-site activation.

Retail and specialty pharmacies are the main channel for Gilead Sciences, Inc.'s chronic oral medicines. Biktarvy and Descovy are both 1-tablet, once-daily regimens, so the channel is built around refill persistence rather than one-time dispensing. Sunlenca adds a different pattern: 2 oral loading doses on days 1 and 2, then 1 injection every 6 months. That type of schedule pushes the prescription through specialty pharmacy workflows, benefit checks, and long-term adherence support.

• Biktarvy and Descovy fit routine retail and specialty pharmacy refill models.
• Sunlenca fits specialty pharmacy and clinic coordination because it is tied to a 6-month dosing interval.
• Oral HIV products create recurring prescription volume, which is different from the 1-time hospital model used for CAR-T therapies.

Global licensing networks expand access beyond Gilead Sciences, Inc.'s owned commercial channels. Gilead Sciences, Inc. markets medicines in more than 130 countries, so licensing matters for markets where direct sales coverage is weaker or not practical. In channel terms, licensing changes the route to market from a branded sale through a field force to a multi-country supply structure. That usually lowers per-unit economics but broadens patient reach, which is important for large-volume public health products.

Direct commercial sales teams are the layer that makes the channel work in daily practice. They connect the product to the physician, the hospital account, the pharmacy hub, and the payer. The portfolio they support spans first approvals in 2016, 2017, 2018, 2020, 2022, and 2024, so the sales motion has to handle mature oral therapies, newer oncology drugs, and highly specialized cell therapy products at the same time. That mix requires different account plans for each product class.

• Oral products need refill continuity and payer access work.
• Infused oncology products need site-level ordering, scheduling, and reimbursement support.
• Cell therapies need treatment-center activation and multi-step care coordination.
• Different approval years mean different lifecycle needs inside the same field organization.

Clinical and medical affairs support the channel by turning data into use. Their role is not just education; it is access creation. Phase 3 evidence supports label use, while phase 4 follow-up shows how a medicine performs after approval. For hospital and specialist channels, this matters because prescribers want practical evidence on administration, toxicity management, and patient selection before they adopt a new therapy. This is especially important for products that require a center-based treatment model rather than a simple retail prescription.

• Phase 3 evidence supports adoption by specialists and hospital committees.
• Phase 4 follow-up supports long-term safety and real-world use.
• Medical affairs also supports dosing, handling, and referral-pathway training.
• For cell therapy, scientific support is tied directly to site readiness and patient flow.

Gilead Sciences, Inc. - Canvas Business Model: Customer Segments

HIV treatment patients are the largest and most durable segment. 39.9 million people were living with HIV in 2023, and 30.7 million were receiving antiretroviral therapy, so the core market is a repeat-prescription population with long treatment duration.

• 39.9 million people living with HIV in 2023.
• 30.7 million people on antiretroviral therapy in 2023.
• 630,000 AIDS-related deaths in 2023.

HIV prevention patients are defined by incidence rather than prevalence. 1.3 million new HIV infections in 2023 set the size of the prevention opportunity, and long-acting prevention matters because it reduces daily-pill dependence.

• 1.3 million new HIV infections in 2023.
• 120 countries in access coverage structures.
• 25.9 million people living with HIV in sub-Saharan Africa in 2023.

Oncology patients and oncologists form a specialist segment with large disease volume. 20 million new cancer cases and 9.7 million cancer deaths in 2022 create demand for hospital and clinic delivery, while oncologists remain the main prescribers.

• 20 million new cancer cases in 2022.
• 9.7 million cancer deaths in 2022.
• 2 core burden metrics define the segment: incidence and mortality.

Liver disease patients remain relevant through chronic hepatitis B and hepatitis C. 254 million people were living with chronic hepatitis B in 2022, and 50 million were living with chronic hepatitis C in 2022, which keeps antiviral demand tied to screening, treatment, and follow-up.

• 254 million chronic hepatitis B cases in 2022.
• 50 million chronic hepatitis C cases in 2022.
• 2 major viral liver diseases anchor the segment.

Global access markets are sized by geography and disease burden. 120 countries in access coverage structures and 25.9 million people living with HIV in sub-Saharan Africa in 2023 show why lower-income markets matter for volume, pricing, and public-sector procurement.

• 120 countries in access coverage structures.
• 25.9 million people living with HIV in sub-Saharan Africa in 2023.
• 6 generic manufacturers were included in one lenacapavir access structure.

Gilead Sciences, Inc. - Canvas Business Model: Cost Structure

$4.8B in research and development expense and $6.2B in cost of product sales.

$32.0B in cumulative capital investments.

• $4.8B R&D expense
• $6.2B cost of product sales
• $32.0B cumulative capital investments

Gilead Sciences, Inc. - Canvas Business Model: Revenue Streams

HIV product sales

• Biktarvy $13.4 billion
• Descovy $3.0 billion
• Genvoya $2.2 billion
• Odefsey $1.1 billion
• Symtuza $0.8 billion
• Truvada $0.6 billion
• Total $21.1 billion

Oncology product sales

• Yescarta $1.6 billion
• Trodelvy $1.3 billion
• Tecartus $0.7 billion
• Total $3.6 billion

COVID-19 treatment sales

• Veklury $0.8 billion

Inflammation therapy sales

• Jyseleca $0.1 billion

International licensing revenue

• royalty, contract and other revenue $1.0 billion